HEMOPATIAS MALIGNAS - Instituto de Oncología Ángel H. Roffo

378 PAUTAS DE DIAGNOSTICO Y TRATAMIENTO / INSTITUTO ANGEL H. ROFFO
CLORAMBUCILO + PREDNISONA
CLORAMBUCILO 0.3 mg/kg VO Días 1 al 5
PREDNISONA 40 mg/m 2 VO Días 1 al 5
Ciclos cada 28 días
CVP
CICLOFOSFAMIDA 750 mg/m 2 IV Día 1
VINCRISTINA 1.4 mg/m 2 IV Día 1
PREDNISONA 100 mg VO Días 1 al 5
Ciclos cada 28 días
BIBLIOGRAFIA
79. Crespo M, Bosch F, Villamar N, e al. ZAP-
70 expression as a surrogate for immunoglobulinvariable-region
mutations in chronic lymphocytic
leucemia. N Eng J Med 2003; 348: 1764-1775.
80. Orchard J, Ibbotson R, Davis Z, et al. ZAP-
70 expression and prognosis in chronic
lymphocytic leukemia. Lancet 2004; 363: 105-
111.
81. Rassenti L, Huynh L, Toy T, et al. ZAP-70
compared with immunoglobulin heavy-chain
gene mutation status as a predictor of disease
progresión in chronic lymphocytic leucemia. N
Eng J Med 2004; 351: 893-901.
82. Dohner H., Stilgenbauer S, Benner A, et
al. Genomic aberrations and survival in chronic
lymphocytic leucemia. N Eng J Med 2000; 343:
1910-1916
83. Rai K, Peterson B, Appelbaum F, et al.
Fludarabine compared with chlorambucil as
primary therapy for chronic lymphocyic leukemia.
N Eng J Med 2000; 343: 1750-1757.
84. Hallek M, Schmitt B, Wihelm M, et al.
Fludarabine plus cyclophosphamide is an efficient
treatment for advanced chronic lymphocyic
leukemia (CLL): results of a phase II study of the
German CLL Study Group. Br J Haematol 2001;
114: 342-348.
85. Eichhorst B, Busch R, Hopfinger G, et al.
Fludarabine plus cyclophosphamide (FC) induces
higher remission rates and longer progression
free survival (PFS) than fludarabine (F) alone in
first line therapy for advanced chronic lymphocytic
leukemia (CLL). Results of a Phase III study (CLL
4 Protocol) of the German CLL Study Group
(GCLLSG). Program and abstracts of the 45th
Annual Meeting of the American Society of
Haematology. December 6-9 2003; San Diego,
California. Abstract 243.
86. Flinn I, Kumm E, Grever M, et al.
Fludarabine and cyclophosphamide produces a
higher complete response rate and more durable
remissions than fludarabine in patients with
previously untreated CLL. Program and abstracts
of the 46th Annual Meeting of the American
Society of Haematology. December 4-7 2004;
San Diego, California. Abstract 475.
87. O´Brien S, Kantarjian H, Cortes J, et al.
Results of the fludarabine and cyclophosphamide
combination regimen in chronic lymphocytic
leukemia. J Clin Oncol 2001; 19(5): 1414-1420.
88. O´Brien S, Kantarjian H., Thomas D, et al.
Rituximab dose escalation trial in chronic
lymphocytic leukemia. J Clin Oncol 2001; 19:
2165-2170.
89. Byrd J, Peterson B, Morrison V, et al.
Randomizef phase 2 study of fludarabine with
concurrent versus sequential treatment with
rituximab in symptomatic, untreated patients
woth B-cell chronic lymphocytic leukemia: results
from Cancer and Leukemia Group B 9712 (CALGB
9712). Blood 2003; 101: 6-14.
90. Byrd J, Rai K, Peterson B, et al. Addition
of rituximab to fludarabine may prolong
progression free survival and overall survival in
patients with previously untreated chronic
lymphocytic leukemia: an updated retrospective
comparative analysis of CALG 9712 and CALG
9011. Blood 2005; 105: 49-53.
91. Keating M, O´Brien S, Albitar M, et al.
Early results of a chemoimmunotherapy regimen
of fludarabine, cyclophosphamide and rituximab
as initial therapy for chronic lymphocytic
leukemia. J Clin Oncol 2005; 23: 4079-4088.
92. Keating M, Flinn I, Jain V, et al. Therapeutic
role of alentuzumab (Campath 1H) in patients
who have failed fludarabine: results of a large
international study. Blood 2002; 99: 3554-3561.
93. Moreton P, Kwnnwsy B, Lucas G, et al.
Erradication of minimal residual disease in B-cell
chronic lymphocytic luekemia after alemtuzumab
therapy is associated with prolonged survival. J
Clin Oncol 2005; 23: 2971-2979.
94. Mortillo M, Tedeschi A, Rossi V, et al.
Alentuzumab as consolidation after a response
to fludarabine is effective to purge residual
disease in patients with chronic lymphocytic
leukemia. Program and abstracts of the 46th